Anti-inflammatory |
Inhibition of release IL-6,IL-8,IL-10 TNF-α Activation NF-κB, cytokines, PGE2
|
Human monocytes, mouse macrophage cells, murine splenocytes |
[102,104,105] |
Inhibition on nitric oxide production |
Mouse macrophage |
[102] |
Antidiabetic |
Reduction of gastric mucosal demage |
Wister rat model |
[22] |
Inhibition of α-glucosidase, lipase and amylase |
In vitro model studies |
[115,117] |
Modulation of multiple pathways associated with insulin signaling |
Rats on fructose-rich diet, in vivo, in vitro studies |
[118,119] |
Restoring of beta cells integrity |
In vivo models |
[116,120,121] |
Cardioprotective |
Lipid metabolism–decrease of cholesterol synthesis |
Caco-2-cells |
[125] |
-Inhibition of LDL oxidation, lipid peroxidation |
Patients with metabolic syndrome |
[20] |
-Increase activity of glutathione peroxidase and catalase, reduction of LDL cholesterol -Inhibition of platelet aggregation, protein carbonylation and thiol oxidation |
Mens with hypercholesterolemia |
[128] |
Anticoagulant, antithrombotic -Decrease in fibrin polymerization |
Human plasma |
[23,25,123] |
-Inhibition of platelet aggregation, protein carbonylation and thiol oxidation |
Human plasma, purified fibrinogen |
[95,120,129,130,131] |
Decrease blood pressure |
|
|
-inhibition of angiotensis I-converting enzyme ACE |
Patients with metabolic syndrome |
[135] |
Protection of coronary arteries |
|
Coronary vasoactive, vasoprotective effect |
Caco-2-cells |
Decrease oxidative stress—stimulation of endothelial formation of NO |
Porcine coronary arteries |
Anticancer |
Inhibition of oxidation |
Caco-2-cells line |
[138] |
Reduction of oxidative stress |
Human granulocytes, HeLa cervical tumor line, murine leukemia cells, brest cancer patients |
[94,98,130,139,141] |
Induction of apoptosis |
Lymphoblastic leukemia Jurkat cell line |
[141] |
Blockage at G1/G0 and G2/M phases of cell cycle |
Human colon cancer |
[142] |